Physician profile
Harmeet Singh Sachdev
NPI 1023076361
$24,621.04
in general payments reported to CMS, 2019-2025
72 companies · $3,142 in 2025
The $3,142 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,703 · 2020: $1,715 · 2021: $2,993 · 2022: $2,800 · 2023: $3,606 · 2024: $3,662 · 2025: $3,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,398.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,284.95 | 2019 | |
| Biogen, INC. | $1,857.06 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $1,728.50 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $1,459.99 | 2019-2025 | |
| Eisai INC. | $1,169.55 | 2019-2025 | |
| Abbvie INC. | $1,119.08 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Catalyst Pharmaceuticals, INC. | $1,044.51 | 2019-2025 | Fycompa |
| Emd Serono, INC. | $927.75 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $871.81 | 2020-2025 | |
| Ucb, INC. | $841.21 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Janssen Pharmaceuticals, INC | $678.74 | 2020-2023 | Ponvory |
| Lundbeck LLC | $565.99 | 2019-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $479.67 | 2019-2025 | |
| Celgene Corporation | $444.35 | 2021-2025 | Zeposia |
| Horizon Therapeutics Plc | $443.41 | 2021-2023 | Uplizna |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $435.19 | 2019-2025 | Ingrezza, Ongentys |
| Portola Pharmaceuticals, LLC | $424.62 | 2019-2020 | |
| Lilly USA, LLC | $414.69 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Neurelis, INC. | $402.49 | 2022-2025 | Valtoco |
| Harmony Biosciences LLC | $397.05 | 2021-2025 | Wakix |
| Kyowa Kirin, INC. | $365.07 | 2020-2024 | Nourianz |
| Mdd US Operations, LLC | $343.66 | 2019-2025 | Apokyn |
| Genentech USA, INC. | $343.30 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Astrazeneca Pharmaceuticals LP | $316.30 | 2021-2024 | Andexxa |
| Teva Pharmaceuticals USA, INC. | $271.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $256.20 | 2023-2025 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $224.09 | 2023-2024 | Aptiom |
| Acorda Therapeutics, INC | $201.48 | 2022-2024 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $192.80 | 2019-2025 | Rytary |
| Supernus Pharmaceuticals, INC. | $188.23 | 2019-2021 | |
| Microtransponder, INC. | $164.07 | 2025 | |
| Chiesi USA, INC. | $163.26 | 2019-2024 | Cleviprex |
| Biohaven Pharmaceuticals, INC. | $160.90 | 2020-2021 | |
| Amgen INC. | $157.97 | 2019-2025 | Uplizna |
| Csl Behring | $156.50 | 2019-2025 | Hizentra |
| Avanir Pharmaceuticals, INC. | $155.24 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $141.84 | 2019-2024 | Nuplazid |
| Banner Life Sciences, LLC | $138.39 | 2021-2024 | |
| Biotronik INC. | $125.09 | 2019 | |
| Ani Pharmaceuticals, INC. | $118.75 | 2022-2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $114.62 | 2025 | |
| Sunovion Pharmaceuticals INC. | $111.25 | 2019-2022 | |
| Pfizer INC. | $109.39 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $104.63 | 2019-2021 | |
| Akcea Therapeutics, INC. | $94.55 | 2019-2020 | |
| Janssen Biotech, INC. | $62.57 | 2025 | |
| Alfasigma USA, INC. | $62.23 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $61.95 | 2022-2023 | Onpattro |
| Mallinckrodt Hospital Products INC. | $58.63 | 2023 | Acthar |
| Ge Healthcare | $57.65 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $55.17 | 2021 | |
| Vertical Pharmaceuticals, LLC | $53.13 | 2019 | |
| Allergan, INC. | $45.92 | 2020 | |
| Boston Scientific Corporation | $44.52 | 2024 | Watchman Flx |
| Octapharma USA, INC. | $38.40 | 2024-2025 | Panzyga, Fibryga |
| Merz Pharmaceuticals, LLC | $36.06 | 2024 | |
| Vanda Pharmaceuticals INC. | $32.79 | 2025 | Ponvory |
| Merz North America, INC. | $32.51 | 2019 | |
| Bausch Health US, LLC | $28.83 | 2019 | |
| Livanova USA, INC. | $27.89 | 2020 | |
| Argenx US, INC. | $26.14 | 2024 | Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $25.09 | 2025 | Symbravo |
| Mallinckrodt Enterprises LLC | $23.52 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.36 | 2022 | |
| Electromed, INC. | $17.51 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.20 | 2023 | Elyxyb |
| Arbor Pharmaceuticals, INC. | $15.49 | 2021 | |
| Surgenex LLC | $14.37 | 2025 | Surmatrix, Pellograft, Surgraft |
| Tanabe Pharma America, INC. | $13.96 | 2019 | |
| Ceribell, INC. | $13.88 | 2024 | Pocket Eeg Device |
| Upsher-Smith Laboratories LLC | $13.06 | 2020 | |
| Assertio Therapeutics, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmeet Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.